Download PDF
Erfahrungsheilkunde 2021; 70(04): 199-203
DOI: 10.1055/a-1528-4267
Wissen

Kava – 20 Jahre Kampf gegen regulatorische Windmühlenflügel

Mathias Schmidt
› Further Information
    Permissions and Reprints

Zusammenfassung

Arzneimittel auf der Basis von Extrakten aus den Wurzeln der Kavapflanze (Piper methysticum) waren in Deutschland bis zum Widerruf der Zulassungen am 14. Juni 2002 sehr beliebte Mittel gegen nervöse Angst-, Spannungs- und Unruhezustände. Kava ist eine der am besten untersuchten Arzneipflanzen, sowohl aus pharmakologischer Sicht als auch durch klinische Evidenz und Jahrhunderte traditioneller Erfahrung der sicheren Anwendung im Südpazifik. Noch bleibt Hoffnung, dass die behördliche Entscheidung revidiert werden kann.

Abstract

Until the revocation of marketing authorizations in Germany on June 14, 2002, medicinal products based on extracts of the roots of the kava plant (Piper methysticum) were popular remedies against states of nervous anxiety, tension and restlessness. Kava is one of the best researched medicinal plants, as much from the pharmacological point of view as by clinical evidence and centuries of traditional experience of safe use in the South Pacific. Hope still remains that the regulatory decision can be revised.

Schlüsselwörter

Piper methysticum - Stufenplanverfahren - Noble Kava - Twoday Kava - Hepatotoxizität

Key words

Piper methysticum - Drug safety protocol - Noble Kava - Twoday Kava - Hepatotoxicity


Publication History

Article published online:
23 August 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Anonymous. Der Widerruf von Kava-Kava ist nicht rational begründet! Interview mit Prof. G. Franz. NaturaMed 2002; 17: 13
    PubMedGoogle Scholar
  • 2 Anonymous. Experten gegen den Widerruf der Zulassung. Kava-Kava nützt den Patienten. Medical Trib 2002; 37
    PubMedGoogle Scholar
  • 3 Anonymous. Kava-Kava: Eine Lücke, die keiner wollte. Interview mit Prof. Volker Faust. NaturaMed 2002; 17: 14
    PubMedGoogle Scholar
  • 4 WHO. Rhizoma Piperis methystici. WHO Monographs on Selected Medicinal Plants. Geneva: World Health Organization; 2002: 231-245
    Google Scholar
  • 5 Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann Hepatol 2009; 8 (01) 4-8
    CrossrefPubMedGoogle Scholar
  • 6 Capasso A, Sorrentino L. Pharmacological studies on the sedative and hypnotic effect of Kava Kava and Passiflora extracts combination. Phytomed 2005; 12: 39-45
    CrossrefPubMedGoogle Scholar
  • 7 Danan G, Teschke R. RUCAM in drug and herb induced liver injury. The update. Int J Mol Sci 2016; 17: 14
    CrossrefPubMedGoogle Scholar
  • 8 ESCOP. Piperis methystici Rhizoma. In: ESCOP Monographs – The Scientific Foundation for Herbal Medicinal Products. Stuttgart: Thieme; 2003: 365-382
    Google Scholar
  • 9 European Association for the Study of the Liver. EASL clinical practical guidelines on the management of acute (fulminant) liver failure. J Hepatol 2017; 66: 1047-1081
    CrossrefPubMedGoogle Scholar
  • 10 Garrett KM, Basmadjian G, Khan IA. et al. Extracts of kava (Piper methysticum) induce acute anxiolytic-like behavioral changes in mice. Psychopharmacol 2003; 170: 33-41
    CrossrefPubMedGoogle Scholar
  • 11 HMPC. EMA/HMPC/450589/2016. Assessment Report on Piper methysticum G. Forst., Rhizoma. London: European Medicines; 2017
    Google Scholar
  • 12 Kohlenberg FJ. Pharmakologische Untersuchungen zum Wirkungsspektrum von Piper methysticum G. Forst., Piperaceae. Münster: Westfälische Wilhelms-Universität, Fachbereich Chemie und Pharmazie der Mathematisch-Naturwissenschaftlichen Fakultät; 1999: 1-225
    Google Scholar
  • 13 Kraft K. Verwaltungsgericht Köln kippt das Kava-Verbot. Z Phytother 2014; 35: 186-189
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Kuchta K, Hladikova M, Thomsen M. et al. Kava (Piper methysticum) extract for the treatment of nervous anxiety, tension and restlessness. Drug Res 2021; 71: 83-93
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Kuchta K, Schmidt M, Nahrstedt A. German Kava ban lifted by court: The alleged hepatotoxicity of Kava (Piper methysticum) as a case of ill-defined herbal drug identity, lacking quality control, and misguided regulatory politics. Planta Med 2015; 81: 1647-1653
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 LaPorte E, Sarris J, Stough C. et al. Neurocognitive effects of kava (Piper methysticum): A systematic review. Hum Psychopharmacol 2011; 26: 102-111
    CrossrefPubMedGoogle Scholar
  • 17 Lebot V, Merlin M, Lindstrom L. Kava, the Pacific elixir. New Haven: Yale University; 1992
    CrossrefGoogle Scholar
  • 18 Lebot V, Michalet S, Legendre L. Kavalactones and flavokavins profiles contribute to quality assessment of Kava (Piper methysticum G. Forst.), the traditional beverage of the Pacific. Beverages 2019; 5: 34
    CrossrefPubMedGoogle Scholar
  • 19 Lhuissier T, Mercier PE, Michalet S. et al. Colorimetric assessment of kava (Piper methysticum Forst.) quality. J Food Compos Anal 2017; 59: 27-34
    CrossrefPubMedGoogle Scholar
  • 20 Pittler MH, Ernst E. Kava extract for treating anxiety (Cochrane review). Cochrane: The Cochrane Library; 2003: CD003383
    PubMedGoogle Scholar
  • 21 Schmidt M. Quality criteria for kava. Herbal Gram 2007; 73: 44-49
    PubMedGoogle Scholar
  • 22 Schmidt M, Nahrstedt A. Ist Kava lebertoxisch? Eine Analyse der bekannten Daten zum Leberrisiko von Kava-Präparaten. Dt Apoth Ztg 2002; 142: 1006-1011
    PubMedGoogle Scholar
  • 23 Schmidt M, Nahrstedt A, Lüpke NP. Piper methysticum (Kava) in der Diskussion: Betrachtungen zu Qualität, Wirksamkeit und Unbedenklichkeit. Wien Med Wschr 2002; 152: 382-388
    CrossrefPubMedGoogle Scholar
  • 24 Shi Y, Dong JW, Zhao JH. et al. Herbal insomnia medications that target GABAergic systems: A review of the psychopharmacological evidence. Curr Neuropharmacol 2014; 12: 289-302
    CrossrefPubMedGoogle Scholar
  • 25 Siméoni P, Lebot V. Buveurs de Kava. Port Vila. Vanuatu: Géo-Consulte;: 2014
    PubMedGoogle Scholar
  • 26 Singh YN. Kava. From Ethnology to Pharmacology. Boca Raton, London, New York, Washington: CRC Press; 2004
    CrossrefGoogle Scholar
  • 27 Smith KK, Dharmaratne HR, Feltenstein MW. et al. Anxiolytic effects of kava extract and kavalactones in the chick social separation-stress paradigm. Psychopharmacol 2001; 155: 86-90
    CrossrefPubMedGoogle Scholar
  • 28 Tafesh ZH, Pyrsopoulos N. Classification and epidemiologic Aspects of Acute and Acute on Chronic Liver Failure. In: Pyrsopoulos N. Hrsg. Liver Failure – Acute and Acute on Chronic. Cham: Springer; 2020: 1-18
    Google Scholar
  • 29 Teschke R, Fuchs J, Bahre R. et al. Kava hepatotoxicity: Comparative study of two structured quantitative methods for causality assessment. J Clin Pharm Ther 2010; 35: 545-563
    CrossrefPubMedGoogle Scholar
  • 30 Teschke R, Gaus W, Loew D. Kava extracts: Safety and risks including rare hepatotoxicity. Phytomed 2003; 10: 440-446
    CrossrefPubMedGoogle Scholar
  • 31 Teschke R, Schwarzenboeck A, Hennermann KH. Kava hepatotoxicity: A clinical survey and critical analysis of 26 suspected cases. Eur J Gastroenterol Hepatol 2008; 20: 1182-1193
    CrossrefPubMedGoogle Scholar
  • 32 Teschke R, Wolff A. Kava hepatotoxicity: regulatory data selection and causality assessment. Dig Liver Dis 2009; 41: 891-901
    CrossrefPubMedGoogle Scholar
  • 33 Teschke R, Wolff A. Regulatory causality evaluation methods applied in kava hepatotoxicity: Are they appropriate?. Regul Toxicol Pharmacol 2011; 59: 1-7
    CrossrefPubMedGoogle Scholar
  • 34 Thomsen M, Schmidt M. Health policy versus kava (Piper methysticum): Anxiolytic efficacy may be instrumental in restoring the reputation of a major South Pacific crop. J Ethnopharmacol 2021; 268: 113582
    CrossrefPubMedGoogle Scholar
  • 35 Weiler N, Schlotmann A, Schnitzbauer AA. et al. Epidemiologie des akuten Leberversagens. Dt Ärztebl Int 2020; 117: 43-50
    PubMedGoogle Scholar